Literature DB >> 19589030

Systemic therapy for recurrent endometrial cancer: a review of North American trials.

Thanh H Dellinger1, Bradley J Monk.   

Abstract

While early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trials is only approximately 1 year. This review will discuss the developments of systemic therapy in recurrent endometrial cancer, focusing on North American trials, in particular those documenting recent progress in new drug developments, as well as the future of individualized treatment regimens.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19589030     DOI： 10.1586/era.09.54

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  22 in total

1.  Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.

Authors:  Janelle B Pakish; Qian Zhang; Zhongyuan Chen; Han Liang; Gary B Chisholm; Ying Yuan; Samuel C Mok; Russell R Broaddus; Karen H Lu; Melinda S Yates
Journal:  Clin Cancer Res       Date:  2017-03-06       Impact factor: 12.531

2.  Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.

Authors:  Thanh H Dellinger; Kestutis Planutis; Danielle D Jandial; Ramez N Eskander; Micaela E Martinez; Xiaolin Zi; Bradley J Monk; Randall F Holcombe
Journal:  Gynecol Oncol       Date:  2012-04-30       Impact factor: 5.482

Review 3.  Current status of molecular biomarkers in endometrial cancer.

Authors:  H M J Werner; H B Salvesen
Journal:  Curr Oncol Rep       Date:  2014-09       Impact factor: 5.075

4.  Sulfated glycolipid PG545 induces endoplasmic reticulum stress and augments autophagic flux by enhancing anticancer chemotherapy efficacy in endometrial cancer.

Authors:  Robert Hoffmann; Sayantani Sarkar Bhattacharya; Debarshi Roy; Boris Winterhoff; Ralf Schmidmaier; Keith Dredge; Edward Hammond; Viji Shridhar
Journal:  Biochem Pharmacol       Date:  2020-04-28       Impact factor: 5.858

Review 5.  New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?

Authors:  Victor Rodriguez-Freixinos; Katherine Karakasis; Amit M Oza
Journal:  Curr Oncol Rep       Date:  2016-04       Impact factor: 5.075

Review 6.  Immunotherapy in Gynecologic Cancers: Are We There Yet?

Authors:  Janelle B Pakish; Amir A Jazaeri
Journal:  Curr Treat Options Oncol       Date:  2017-08-24

7.  Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.

Authors:  Ramez N Eskander; Tao Ji; Be Huynh; Rooba Wardeh; Leslie M Randall; Bang Hoang
Journal:  Int J Gynecol Cancer       Date:  2013-07       Impact factor: 3.437

8.  Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.

Authors:  Kosei Hasegawa; Masahiro Kagabu; Mika Mizuno; Katsutoshi Oda; Daisuke Aoki; Seiji Mabuchi; Shoji Kamiura; Satoshi Yamaguchi; Yoichi Aoki; Toshiaki Saito; Mayu Yunokawa; Kazuhiro Takehara; Aikou Okamoto; Kazunori Ochiai; Tadashi Kimura
Journal:  Invest New Drugs       Date:  2017-09-02       Impact factor: 3.850

Review 9.  Molecular targeted therapy in gynaecologic malignancies: primer for radiologists.

Authors:  Chong Hyun Suh; Sree H Tirumani; Abhishek Keraliya; Kyung Won Kim; Nikhil H Ramaiya; Atul B Shinagare
Journal:  Br J Radiol       Date:  2016-07-12       Impact factor: 3.039

Review 10.  PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.

Authors:  Felicia Roncolato; Kristina Lindemann; Melina L Willson; Julie Martyn; Linda Mileshkin
Journal:  Cochrane Database Syst Rev       Date:  2019-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.